| ［1］ |
Ständer S, Luger TA. NK⁃1 antagonists and itch［J］. Handb Exp Pharmacol, 2015,226:237⁃255. doi: 10.1007/978⁃3⁃662⁃44605⁃8_14.
|
| ［2］ |
Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study［J］. Lancet Oncol, 2012,13（10）:1020⁃1024. doi: 10.1016/S1470⁃2045（12）70373⁃X.
|
| ［3］ |
Zic JA, Straka BT, McGirt LY, et al. Aprepitant for the treatment of pruritus in Sézary syndrome: a randomized crossover clinical trial［J］. JAMA Dermatol, 2018,154（10）:1221⁃1222. doi: 10.1001/jamadermatol.2018.2510.
|
| ［4］ |
Lönndahl L, Holst M, Bradley M, et al. Substance P antagonist aprepitant shows no additive effect compared with standardized topical treatment alone in patients with atopic dermatitis［J］. Acta Derm Venereol, 2018,98（3）:324⁃328. doi: 10.2340/00015555⁃2852.
|
| ［5］ |
Tsianakas A, Zeidler C, Riepe C, et al. Aprepitant in anti⁃histamine⁃refractory chronic nodular prurigo: a multicentre, randomized, double⁃blind, placebo⁃controlled, cross⁃over, phase⁃II trial （APREPRU）［J］. Acta Derm Venereol, 2019,99（4）:379⁃385. doi: 10.2340/00015555⁃3120.
|
| ［6］ |
Frenkl TL, Zhu H, Reiss T, et al. A multicenter, double⁃blind, randomized, placebo controlled trial of a neurokinin⁃1 receptor antagonist for overactive bladder［J］. J Urol, 2010,184（2）:616⁃622. doi: 10.1016/j.juro.2010.03.147.
|
| ［7］ |
Yosipovitch G, Ständer S, Kerby MB, et al. Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo⁃controlled phase 2 clinical trial［J］. J Am Acad Dermatol, 2018,78（5）:882⁃891.e10. doi: 10.1016/j.jaad. 2018.02.030.
|
| ［8］ |
Ständer S, Kwon P, Hirman J, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2019,80（5）:1395⁃1402. doi: 10.1016/j.jaad.2019.01.052.
|
| ［9］ |
Chiou AS, Choi S, Barriga M, et al. Phase 2 trial of a neurokinin⁃1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: a randomized clinical trial［J］. J Am Acad Dermatol, 2020,82（6）:1415⁃1421. doi: 10.1016/j.jaad.2019. 09.014.
|
| ［10］ |
Pariser DM, Bagel J, Lebwohl M, et al. Serlopitant for psoriatic pruritus: a phase 2 randomized, double⁃blind, placebo⁃controlled clinical trial［J］. J Am Acad Dermatol, 2020,82（6）:1314⁃1320. doi: 10.1016/j.jaad.2020.01.056.
|
| ［11］ |
Welsh SE, Xiao C, Kaden AR, et al. Neurokinin⁃1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial［J］. J Eur Acad Dermatol Venereol, 2021,35（5）:e338⁃e340. doi: 10. 1111/jdv.17090.
|
| ［12］ |
Steinhoff M, Bienenstock J, Schmelz M, et al. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus［J］. J Invest Dermatol, 2006,126（8）:1705⁃1718. doi: 10.1038/sj.jid.570 0231.
|
| ［13］ |
Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of ct327 in a phase 2b clinical trial in patients with psoriasis［J］. Acta Derm Venereol, 2015,95（5）:542⁃548. doi: 10.2340/00015555⁃2047.
|
| ［14］ |
Palkar R, Ongun S, Catich E, et al. Cooling relief of acute and chronic itch requires TRPM8 channels and neurons［J］. J Invest Dermatol, 2018,138（6）:1391⁃1399. doi: 10.1016/j.jid.2017. 12.025.
|
| ［15］ |
Ständer S, Augustin M, Roggenkamp D, et al. Novel TRPM8 agonist cooling compound against chronic itch: results from a randomized, double⁃blind, controlled, pilot study in dry skin［J］. J Eur Acad Dermatol Venereol, 2017,31（6）:1064⁃1068. doi: 10. 1111/jdv.14041.
|
| ［16］ |
Ständer S, Moormann C, Schumacher M, et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures［J］. Exp Dermatol, 2004,13（3）:129⁃139. doi: 10.1111/j.0906⁃6705.2004. 0178.x.
|
| ［17］ |
Lee JH, Choi CS, Bae IH, et al. A novel, topical, nonsteroidal, TRPV1 antagonist, PAC⁃14028 cream improves skin barrier function and exerts anti⁃inflammatory action through modulating epidermal differentiation markers and suppressing Th2 cytokines in atopic dermatitis［J］. J Dermatol Sci, 2018:S0923⁃1811（18）30204⁃4. doi: 10.1016/j.jdermsci.2018.04.017.
|
| ［18］ |
Datsi A, Steinhoff M, Ahmad F, et al. Interleukin⁃31: the "itchy" cytokine in inflammation and therapy［J］. Allergy, 2021,76（10）:2982⁃2997. doi: 10.1111/all.14791.
|
| ［19］ |
Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate⁃to⁃severe atopic dermatitis: randomized, phase II, long⁃term extension study［J］. J Allergy Clin Immunol, 2018,142（4）:1121⁃1130.e7. doi: 10.1016/j.jaci.2018.03.018.
|
| ［20］ |
Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus［J］. N Engl J Med, 2020,383（2）:141⁃150. doi: 10.1056/NEJMoa1917006.
|
| ［21］ |
Kumada H, Miyakawa H, Muramatsu T, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double⁃blind trial［J］. Hepatol Res, 2017,47（10）:972⁃982. doi: 10.1111/hepr.12830.
|
| ［22］ |
Mathur VS, Kumar J, Crawford PW, et al. A multicenter, randomized, double⁃blind, placebo⁃controlled trial of nalbuphine ER tablets for uremic pruritus［J］. Am J Nephrol, 2017,46（6）:450⁃458. doi: 10.1159/000484573.
|
